Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. - Wikidata - awgldk - TriplyDB

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

http://www.wikidata.org/entity/Q33427353

about

Trastuzumab containing regimens for early breast cancer Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials Radiotherapy and "new" drugs-new side effects?Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant Radiotherapy The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Radiation pneumonitis and pulmonary function with lung dose-volume constraints in breast cancer irradiation.Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study.Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age.Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab Targeted therapies in breast cancer: are heart and vessels also being targeted?Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.Current concepts in clinical radiation oncology.Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.ACR Appropriateness Criteria® conservative surgery and radiation--stage I and II breast carcinoma: expert panel on radiation oncology: breast.Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis.Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.Breast cancer therapy-associated cardiovascular disease.Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy.Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer.Cardiotoxicity associated with targeted cancer therapies.Assessment of concomitant versus sequential trastuzumab on radiation-induced cardiovascular toxicity.Trastuzumab-associated cardiac events in the Persephone trial.Long-Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study.Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.Occurrence of pneumonitis following radiotherapy of breast cancer - A prospective study.Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.Trastuzumab-related cardiac events in the treatment of early breast cancer.Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes.

P2860

Q24200192-CB6B41D3-128F-4C57-940F-54C3C70CD60B Q26776288-8BB40824-CA80-4A8C-9CFD-0993CC0AAD7F Q26861498-FFDAF2AD-37CE-4A26-9CDB-12F9F85F3D71 Q27007849-6ECF1C5E-9981-4E44-8F00-4173CA5529CB Q28068290-BD0480CC-55B8-4966-91FC-99614DBED884 Q30249335-D6807F4C-2D11-49CE-98D0-43041A25FEDA Q30318610-0F978B44-0A36-42AC-9681-E6909C9BEACB Q33595716-BD4E286A-41D6-490F-BDF8-9FC113440BFF Q33709842-640D6C8C-45E7-455A-B35F-2A283BECA6F9 Q33831903-3E54C65B-0D67-4825-89CE-12DEF7447977 Q34316748-2C34EBDA-5D36-4BA2-B2FD-F3B362480663 Q34779675-2C44C199-CF41-405A-A6C6-C215DAACED3F Q35555989-35720693-0D53-406D-8D24-497DAA578F58 Q35583779-E29FE33C-F94F-416C-B25F-63439B783FAF Q35687465-159BFB4D-C267-486C-B818-C1F3B6EBD71B Q36064820-7B7AD2E7-D542-480E-93F9-3D6C6786D93B Q36245324-702973E6-9953-4ABB-9EDA-F0881818713A Q36729600-A7033311-C2CE-48BA-AE4A-75AB3C39390E Q36884404-1D2C7E8C-563D-43DB-9A28-4DE987DB92E5 Q37603804-835FD66B-A8F4-468D-99F8-CC33F53AFBD3 Q37657782-623E6D07-BA2D-4D74-B1C7-A2238C10DF3C Q37905913-B770116E-C348-4628-8479-BFAA0E723429 Q38103465-9DAFFD02-4D3E-4E83-A9F0-06CDF7F8C63C Q38639456-ED43ABC1-0CF6-4E8D-8C46-18AC9085A5D8 Q38645182-2EDAFCAD-36A6-4A44-B8AA-4C6691F86E75 Q38784568-8E0DA161-7977-4401-A35D-3AF551D1676C Q38792791-31E05EEB-8500-4142-83B7-8C4F11B6C793 Q38819670-90647643-293D-41E0-9D95-229774F070C7 Q39117949-A24C9F66-4964-49FF-809A-5CCB6C27159B Q39163356-E6CF4E48-3B6D-4E97-8147-98AFF2276E16 Q39321063-694CA730-9B39-4A86-B841-E12B9472521B Q40353199-0E101E38-B1B6-4C5A-B60B-8FAB88BF9282 Q42911854-B31F9C36-801C-451C-BD5F-5FC388778BC9 Q44652733-F8C38ABF-FCF5-4697-AFC2-2AF5443610E0 Q47116524-6C5FD5A7-8518-42D3-BA1A-37267630F210 Q49950515-501FFB7C-17EC-4030-B90C-EB04A6DE607F Q50720975-26DA83B1-4A24-4093-B93B-F3E10333E535 Q51715669-45460D82-EE56-4880-8BCD-0AD48FB1DEA8 Q54705428-C79885DC-1882-4FEA-A89A-7B1114E62B8E Q54962745-0B6DD0D7-DE34-4A1C-BE01-D49252618281

P2860

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

http://www.wikidata.org/entity/Q33427353

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Radiotherapy and adjuvant tras ...... e NCCTG Phase III Trial N9831.

@ast

Radiotherapy and adjuvant tras ...... e NCCTG Phase III Trial N9831.

@en

type

label

Radiotherapy and adjuvant tras ...... e NCCTG Phase III Trial N9831.

@ast

Radiotherapy and adjuvant tras ...... e NCCTG Phase III Trial N9831.

@en

prefLabel

Radiotherapy and adjuvant tras ...... e NCCTG Phase III Trial N9831.

@ast

Radiotherapy and adjuvant tras ...... e NCCTG Phase III Trial N9831.

@en

P1433

Q33427353-D9DF9322-A340-40D1-9600-CFF1C94143E8

P1476

Q33427353-B2D100CE-3A0C-4953-8DB1-8B9A0F3D1FD2

P2093

Q33427353-0B241368-7DE9-424E-AC1E-5940F7844D2C

Q33427353-1523F55F-DDF5-413B-B175-283D7DAE45A7

Q33427353-18396B2A-4BD8-4E59-B7CF-E80F96777A22

Q33427353-39C1BFCB-AE29-4469-AC99-12CD5AD4F430

Q33427353-531BB9AF-6ADD-4803-AE56-419A3CE1202A

Q33427353-6E2B5D53-D027-43AE-ADA5-474090829B97

Q33427353-70918C7E-5932-45AA-A14E-40E7284EC436

Q33427353-9ECA0EBA-78F5-48FD-B238-5BED0D5A563E

Q33427353-ACD32839-BE86-42C7-90E4-26E75C68D43F

Q33427353-BF3D0813-76F1-4E77-AFC8-E11217FAA241

P2860

Q33427353-03047A2E-04C1-4AA7-BB5F-3F357A4E397F

Q33427353-14881FB6-C76F-46BA-AEEE-CDA87229C266

Q33427353-19FF1EC9-1868-4047-AFE9-712F5492A70C

Q33427353-323F3C3E-A248-4F62-84AF-405463CA255C

Q33427353-348AF6C7-7E26-4165-BDD6-FC22888FE55E

Q33427353-41622120-87D2-4AEA-BB32-44CDA9ADA6A9

Q33427353-43BCCF81-C62E-409D-9F90-733936A1F01A

Q33427353-459120A1-B20B-445F-9623-C810B9D13239

Q33427353-4B1CFFCC-C583-4C7A-A3F1-A1F87B56DBCD

Q33427353-52779755-BA16-4F85-8119-E3BD64C5C7F8

P304

Q33427353-7598D03C-6818-4424-85C8-B742D922CD79

P31

Q33427353-09C211E9-D643-42E1-BD85-FD962292DA75

P356

Q33427353-A618F871-604D-4BEB-AE4B-13D2A339763A

P407

Q33427353-3557FFF8-C663-4C14-9046-26CCBE7A539A

P433

Q33427353-BAED28A7-E98D-446B-A2DC-89E01CDAD1F8

P478

Q33427353-FB653EB8-32EF-4542-BCAC-ADEA28E34471

P50

Q33427353-8269BBD5-BE96-48FD-B9E8-F13B777AC922

P577

Q33427353-7540E4D0-D82E-4C46-9343-450910276D20

P698

Q33427353-6FB75207-0667-41DF-B436-4DD345DC19A2

P921

Q33427353-0D5DB1C2-2E58-4038-AD98-CE0AE0EC0279

Q33427353-BA5ABDC1-DEFE-470A-B4E5-9A395B49DBCC

P932

Q33427353-086BFEAE-1E12-42CA-B1BB-8E3757294035

P356

JCO.2008.17.9549

P1433

Journal of Clinical Oncology

P1476

Radiotherapy and adjuvant tras ...... he NCCTG Phase III Trial N9831

@en

P2093

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

Larry Marks

http://www.w3.org/2001/XMLSchema#string

Larry Solin

http://www.w3.org/2001/XMLSchema#string

Leila Kutteh

http://www.w3.org/2001/XMLSchema#string

Lori Pierce

http://www.w3.org/2001/XMLSchema#string

Michele Y Halyard

http://www.w3.org/2001/XMLSchema#string

Nancy Davidson

http://www.w3.org/2001/XMLSchema#string

Peter Kaufman

http://www.w3.org/2001/XMLSchema#string

Shaker R Dakhil

http://www.w3.org/2001/XMLSchema#string

Silvana Martino

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Molecular portraits of human breast tumours

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

c-erbB-2 in breast cancer: development of a clinically useful marker.

Clinical cardiac tolerability of trastuzumab.

Risk of cardiac death after adjuvant radiotherapy for breast cancer

Managing high-risk breast cancer

P304

2638-2644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.17.9549

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19349549

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

phase III clinical trial

P932

2690390

http://www.w3.org/2001/XMLSchema#string